Cancer Conversations Podcast – Episode #9: Precision Medicine and Lung Cancer

0

Although lung cancer is only the second most common cancer in the United States, it is by far the deadliest cancer in both men and women. But thanks to advancements in precision medicine, treatments for lung cancer are improving, and many patients are benefiting from these new, targeted therapies.

“When we find we have drugs targeted for a specific genetic mutation driving the cancer, the chance of having someone live longer and feel better is much higher,” says David Jackman, MD, a medical oncologist with Dana-Farber’s Lowe Center for Thoracic Oncology and the institute’s Medical Director for Clinical Pathways. “We’re doubling, tripling, and in some cases quadrupling response rates compared to what we see with traditional chemotherapy.”

(From L-R) David Jackman, MD, Barrett Rollins, MD, PhD, and moderator Anne Doerr.

(From L-R) David Jackman, MD, Barrett Rollins, MD, PhD, and moderator Anne Doerr.

In this Cancer Conversations podcast episode, Jackman joins Dana-Farber Chief Scientific Officer Barrett Rollins, MD, PhD, for a discussion on how precision medicine is being used in cancer treatment today as well as some of the latest research in the field.

Listen to the podcast episode below or click “download” to listen later. Subscribe options are also available via iTunes, Google Play, the Stitcher app, TuneIn app, and RSS.

The Cancer Conversations series features Q&A-style conversations with Dana-Farber physicians, clinicians, and researchers. Topics include breast cancer research, precision cancer medicine, integrative therapies, cancer genetics, and more. Visit the Cancer Conversations page for more episodes and the Dana-Farber podcast page for more cancer podcast series.

Make An Appointment

For adults: 877-442-9599

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

Latest Tweets

Dana-Farber @danafarber
Facing only months to live, Doron Broman came to Dana-Farber hoping for a miracle. Today, Broman is cancer-free:… https://t.co/Mj6jpuPh46
Dana-Farber @danafarber
Expanding access to #bloodcancer clinical trials is the mission of the Blood Cancer Research Partnership:… https://t.co/aGmG83xMSd
Dana-Farber @danafarber
It's Healthcare Decisions Month. Have you thought about your future health care preferences? Here's why you should:… https://t.co/XeRe0BDppf

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.